Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...
Merck releases positive phase 3 data on daily oral HIV drug
In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...